-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

4054 Older Adults with Acute Myeloid Leukemia (AML) Treated in a Pragmatic Trial: How Do Patients' Function and Health-Related Quality of Life Change with Treatment?

Program: Oral and Poster Abstracts
Session: 615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster III
Hematology Disease Topics & Pathways:
Research, clinical trials, Acute Myeloid Malignancies, AML, Non-Biological therapies, elderly, Clinical Research, Chemotherapy, Combination therapy, patient-reported outcomes, Diseases, Therapies, Myeloid Malignancies, Study Population, Human
Monday, December 12, 2022, 6:00 PM-8:00 PM

Vijaya Raj Bhatt, MBBS, MS1*, Christopher Wichman, PhD2*, Zaid S. Al-Kadhimi, MD3*, Thuy T. Koll, MD4*, Alfred L Fisher2*, Ann Berger5*, James O. Armitage, MD6, Sarah A. Holstein, MD, PhD7, Lori Maness, MD3 and Krishna Gundabolu, MBBS3

1The Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE
2University of Nebraska Medical Center, Omaha
3Division of Hematology & Oncology, Department of Internal Medicine, University of Nebraska Medical Center- Fred and Pamela Buffett Cancer Center, Omaha, NE
4Division of Geriatrics, University of Nebraska Medical Center, Omaha, NE
5University of Nebraska Medical Center, Omaha, NE
6Division of Oncology and Hematology, University of Nebraska Medical Center- Fred & Pamela Buffett Cancer Center, Omaha, NE
7Division of Hematology/Oncology, University of Nebraska Medical Center, Omaha, NE

Background: Over one-third of older adults with AML do not receive chemotherapy because of fear of toxicities and functional decline. This highlights the critical and urgent need to generate knowledge of functional changes following newer treatments.

Methods: As a part of a pragmatic single-center phase II investigator-initiated trial (ClinicalTrials.gov ID: NCT03226418), we enrolled older adults (≥60 years) with a new diagnosis of AML. We repeated geriatric assessment (GA) and health-related quality of life (HRQOL) before and 3 months after chemotherapy initiation. GA included measures of physical function (e.g. short physical performance battery or SPPB), Montreal Cognitive Assessment (MoCA), Hematopoietic Cell Transplantation Comorbidity Index, Patient Health Questionnaire-9 (PHQ-9), Mini Nutritional Assessment-Short Form. Frailty was defined as impairment in 2 or more domains on geriatric assessment (excluding MoCA). HRQOL was measured using European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C-30 (v 3.0). Established cutoffs were used to determine a clinically meaningful change in various measures from baseline to 3 months.

Results: 59 eligible patients were enrolled and had median age of 69 years and median KPS of 80. Patients received treatment with predominantly low-intensity chemotherapy (hypomethylating agent +/-venetoclax or midostaurin); six patients received intensive chemotherapy. 56% of patients had ≥2 comorbid conditions, and 69% each had impaired MoCA scores and impaired objective physical function at baseline. Whereas 29% had an established diagnosis of depression or anxiety, 66% had abnormal PHQ-9 with a score of 5 or more. 61% had impaired nutritional screen. A total of 43 patients completed some or all of the optional follow-up assessments at 3 months. Cognitive function or MoCA scores improved (64.5%) or stabilized (9.6%) from baseline to 3 months after treatment (Figure 1). We also noted improvement (51.6%) or stabilization (22.6%) in objective physical function (Figure 2). PHQ-9 scores showed improvement or stabilization in about 90% of patients. Nutritional scores showed variable changes with 40% demonstrating improvement. On HRQOL assessment, global health status score, and role functioning moderately improved from baseline to three-month after enrollment. Longitudinal cognitive function over 3 months differed based on the presence of frailty and multimorbidity (≥2 comorbid conditions) at baseline. Improvement in MoCA scores was noted in 31.8% (95% CI 16.4-52.7%) and 50.0% (95% CI 23.7-76.3%) of patients with versus without baseline frailty. The risk of worsening of cognitive function was 31.5% (95% CI 15.4-54.0%) for patients with multimorbidity at baseline versus 16.7% (95% CI 4.7-44.8%) for those without.

Conclusion: We demonstrated an overall improvement or stabilization of functional status and HRQOL in a high proportion of older adults with AML, despite high prevalence of functional impairments and significant comorbidity burden at baseline. These results should encourage oncologists to offer chemotherapy even to older adults with multiple comorbid conditions or poor functional status at the time of diagnosis of AML.

Disclosures: Bhatt: Servier Pharmaceuticals: Honoraria; Genentech: Honoraria; Incyte: Honoraria, Research Funding; Abbvie: Honoraria, Research Funding; Chimerix: Other: Drug support for a trial; Jazz: Research Funding; National Marrow Donor Program: Research Funding; Pfizer: Research Funding; Protagonist: Other: Member, Safety Monitoring Committee . Al-Kadhimi: Intellia: Current equity holder in private company; Moderna: Current equity holder in private company; Pacific: Current equity holder in private company; Regeneron: Current equity holder in private company. Armitage: Cardiff Oncology: Membership on an entity's Board of Directors or advisory committees. Holstein: Sanofi: Consultancy; Oncopeptides: Consultancy, Research Funding; Janssen: Consultancy, Research Funding; BMS/Celgene: Consultancy, Research Funding; GSK: Consultancy, Research Funding; Takeda: Consultancy, Research Funding; Secura Bio: Consultancy; Genentech: Consultancy. Gundabolu: BioMarin Pharmaceuticals: Honoraria; BMS: Honoraria; Novartis: Honoraria; Blueprint Medicines: Honoraria; Samus: Research Funding; Jazz: Honoraria; Pfizer: Honoraria, Research Funding.

Previous Abstract | Next Abstract >>
*signifies non-member of ASH